Hogan Lovells (Paris) LLP
Hogan Lovells (Paris) LLP houses a team which is known for its ‘broad and deep’ experience in contentious life sciences mandates, and its ’very strong’ expertise in market access issues, data management and protection matters relating to clinical trials, and product liability claims. Notable clients include Eli Lilly, Merck & Co., and GE Healthcare. Practice head Mikael Salmela is noted for his longstanding expertise in handling regulatory assessments and M&A, in addition to product launches and supply transactions. Charlotte Damiano frequently acts for large pharma companies in both contentious and non-contentious matters involving pricing and reimbursement, negotiations with the French health authorities, and the financial regulations governing pharma products.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Both commercial and practical, and take the time to understand our business, providing excellent advice.’
‘The team has broad and deep experience in life sciences litigation. I have worked with them in cross-border pharmaceutical and vaccine litigation for close to two decades. I find them to be smart, responsive, and collaborative.’
‘Charles-Henri Caron is strategic and a good communicator.’
‘Practical spirit, innovative solutions based on knowledge of the healthcare sector and the practices of different stakeholders.’
‘Very strong life sciences expertise.'
'Mikael Salmela and Charlotte Damiano are very practical and understand our business needs.’
Key clients
- Bristol Myers Squibb / Celgene
- Merck & Co., Inc., and its French subsidiary MSD Vaccins
- Eli Lilly
- Icos Corporation
- Voluntis
- Medicrea
- Valneva
- GE Healthcare
- GERON
- Gilead
Work highlights
- Assisted Celgene with a major health data processing authorization request to the CNIL (the French data protection authority) for an innovative drug treatment under a cohort authorization for temporary use (cohort ATU) in France, as well as with the launch and deployment of CAR-T products in France.
- Assisting Merck & Co., Inc., and its French subsidiary MSD Vaccines in the coordination and defence of product liability claims brought by French plaintiffs before the Courts or before Commissions for Conciliation and Indemnification (CCIs) in relation to alleged adverse events of the vaccine Gardasil.
- Represented Lilly on the French aspects of generic attacks on its oncology product, Alimta. The court ordered Fresenius Kabi to pay Eli Lilly damages in the amount of EUR 28m, the highest provisional damages award ordered in a life sciences patent dispute in France (and Europe).
Lawyers
Leading individuals
Practice head
The lawyer(s) leading their teams.
Mikael Salmela